From: Phase II study of lapatinib in combination with vinorelbine, as first or second-line therapy in women with HER2 overexpressing metastatic breast cancer
Lapatinib + vinorelbine (N=44)
Subjects with any SAE, n (%)
22 (50)
With ≥2 (5%) patients,n(%)
Neutropenia
15 (34)*
Diarrhea
3 (7)
Febrile neutropenia
Abdominal pain
2 (5)
Dehydration
Drug-related fatal SAEs, n (%)
0 (0)